Akèy › Neoplazmi myeloproliferatif › Texas › Houston
Etid klinik pou Neoplazmi myeloproliferatif nan Houston, TX
16 etid pou Neoplazmi myeloproliferatif ap chèche patisipan nan sit nan ak bò kote Houston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Ap rekriteFaz 1
- The University of Texas, MD Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Ap rekriteEtid obsèvasyon
- Texas Children's Hospital, Houston
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Ap rekriteFaz 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Ap rekriteFaz 1/2
- MD Anderson, Houston
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
Ap rekriteFaz 1
- M D Anderson Cancer Center, Houston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Ap rekriteFaz 2
- The University of Texas MD Anderson Cancer Center, Houston
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Ap rekriteFaz 1/2
- M D Anderson Cancer Center, Houston
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
Project: Every Child for Younger Patients With Cancer
Ap rekriteEtid obsèvasyon
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Ap rekriteFaz 1
- University of Texas M. D. Anderson Cancer Center, Houston
Asciminib Roll-over Study
Ap rekriteFaz 4
- Uni Of TX MD Anderson Cancer Cntr, Houston
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Ap rekriteFaz 1
- Md Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Ap rekriteFaz 2
- MD Anderson, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Houston
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
Etid Neoplazmi myeloproliferatif nan lòt vil
- New York City, NY15 etid
- Boston, MA14 etid
- Milwaukee, WI10 etid
- Miami, FL10 etid
- Chicago, IL9 etid
- Durham, NC9 etid
- Baldwin Park, CA9 etid
- Seattle, WA9 etid
- Atlanta, GA8 etid
- Tampa, FL8 etid
- Birmingham, AL8 etid
- Columbus, OH8 etid
Lòt etid nan Houston
- Kansè Poumon ki pa ti selil145 etid
- Kansè nan tete126 etid
- Kansè (tout kalite)121 etid
- Kansè Metastatik104 etid
- Kansè kolorektal102 etid
- Kansè ovè89 etid
- Leksemi mieloïd egi85 etid
- Kansè poumon78 etid
- Kansè pwostat76 etid
- Kansè Endomèt68 etid
- Kansè pankreyas61 etid
- Melanom59 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.